Entecavir hydrate

Description	Entecavir monohydrate is an oral antiviral drug used in the treatment of hepatitis B infection. Entecavir monohydrate is a nucleoside analog (more specifically, a guanine analogue) that inhibits reverse transcription, DNA replication and transcription in the viral replication process. Entecavir monohydrate is more efficacious than previous agents used to treat hepatitis B (lamivudine and adefovir). Entecavir monohydrate is also indicated for the treatment of chronic hepatitis B in adults with HIV/AIDS infection. However, Entecavir is not active against HIV. Entecavir cumulative urinary excretion was statistically significant at 45 and 60min. CLR(4°C), CLR(37°C Control) and CLR(37°C Experiment) were 12.6, 27.6 and 36 (ml/min/kg), respectively. CLTS and TR rate (for PEPT2) were 25.3 and 9.4 (ml/min/kg). In vivo, the cumulative urinary excretion of entecavir had statistical significance at 3 and 4h with CLR(Control) and CLR(Experiment) values of 31 and 42 (ml/min/kg), respectively. The CL
Pathways	Microbiology/Virology
Targets	Reverse Transcriptase HBV

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.